Sirexatamab is a monoclonal antibody commercialized by Leap Therapeutics, with a leading Phase II program in Gastric Cancer. According to Globaldata, it is involved in 14 clinical trials, of which 6 were completed, 5 are ongoing, and 3 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Sirexatamab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Sirexatamab is expected to reach an annual total of $59 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Sirexatamab Overview
Leap Therapeutics Overview
Leap Therapeutics is a clinical-stage biopharmaceutical company. It develops novel and targeted drugs to treat patients with different types of cancer. The company’s pipeline includes DKN-01, FL-301, FL-302 and FL-501. DKN-1 is a monoclonal antibody that targets the Dickkopf-1 (DKK-1) protein, intended for the treatment of gastroesophageal cancer, colorectal cancer and gynecological cancer. FL-301 is a monoclonal antibody that targets Claudin18.2 and is being tested in patients with gastric and pancreatic cancer. FL-302 is a tetravalent bispecific antibody that targets both Claudin18.2 and CD137. FL-501 is an antibody designed to neutralize GDF15 and prevent the binding to its receptor. Leap Therapeutics is headquartered in Cambridge, Massachusetts, the US.
The operating loss of the company was US$87 million in FY2023, compared to an operating loss of US$56.8 million in FY2022. The net loss of the company was US$81.4 million in FY2023, compared to a net loss of US$54.6 million in FY2022.
For a complete picture of Sirexatamab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.